



Sesen Bio to Present at the Canaccord Genuity 39th Annual Growth Conference

July 31, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 31, 2019-- **Sesen Bio** (Nasdaq: [SESN](#)), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the Canaccord Genuity 39th Annual Growth Conference on Wednesday, August 7, 2019 in Boston, MA.

Event: Canaccord Genuity 39th Annual Growth Conference

Date: August 7, 2019

Time: 10 a.m. EDT

Location: San Francisco room, The InterContinental Boston Hotel in Boston

A live webcast of the company's presentation will be accessible from the Investors & Media section of Sesen Bio's website, www.sesenbio.com. An archived replay of the webcast will be available on the company's website for 90 days after the conference.

About Sesen Bio

Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The company's lead program, Vicinium[®], also known as VB4-845, is currently in a Phase 3 registration trial, the VISTA trial, for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Vicinium is a locally-administered targeted fusion protein composed of an anti-EPCAM antibody fragment tethered to a truncated form of Pseudomonas Exotoxin A for the treatment of high-risk NMIBC. For more information, please visit the company's website at www.sesenbio.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190731005162/en/>

Source: Sesen Bio, Inc.

Erin Clark, Executive Director, Strategic Planning & Investor Relations
ir@sesenbio.com